Pharmicell Co Ltd (XKRX:005690) Share Price

Company Profile

Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KOR
T: +82 234960114
http://www.pharmicell.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
134

Recommended

Current operating conditions are challenging but over the long-term prospects are better.

Johannes Faul | 25 February 2025

Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.

Joseph Taylor | 25 February 2025

Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.

Morningstar | 25 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,477.30	20.70	-0.24%
CAC 40	8,126.26	75.19	0.93%
DAX 40	22,701.96	291.69	1.30%
Dow JONES (US)	43,621.16	159.95	0.37%
FTSE 100	8,708.74	40.07	0.46%
HKSE	23,787.93	753.91	3.27%
NASDAQ	19,026.39	260.54	-1.35%
Nikkei 225	38,142.37	95.42	-0.25%
NZX 50 Index	12,452.46	145.19	1.18%
S&P 500	5,955.25	0.00	0.00%
S&P/ASX 200	8,240.70	11.20	-0.14%
SSE Composite Index	3,380.21	34.17	1.02%